Navigation Links
Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
Date:7/20/2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... , LIBREVILLE, Gabon, December 2 /PRNew... Africa: Everyone,s Problem and Heritage" , ...versity, 2-3 June 2010 the,Gabonese Republic is ho...abon) on the issue of safeguarding biological reso...y government and state leaders, ministers,scienti...
(Date:12/2/2009)... , SINGAPORE, Dec. 2 S... its novel oral JAK2 inhibitor, SB1518, at The Ame...d Exposition in New Orleans. ,, Data will be pr...ose-escalation trial of SB1518 detailing its safet...c (PK/PD) profile in dose levels ranging from 100 ...
(Date:12/2/2009)... , SHANGHAI, Dec. 2 /PRNewswire-Asia/...; markets are in turmoil and uncertainty is part o...t the pharma industry has been,relatively immune t...ake a,vacation. , During the midst of the...nt Johnson & Johnson inaugurated an R&D ce...
(Date:12/1/2009)... , INCLINE VILLAGE, Nev., Dec. 1 /PRNewswire-...PDLI ) today announced revenue guidance for the fo...ely $57 million, as compared with $69 million for ...rter 2008 results was the first of two installment...luded in fourth quarter 2008 results was a one-tim...
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
...ael and JERSEY CITY, New Jersey, November 3, Roset... development of microRNA-based diagnostics, announ...ference "Translational Cancer Medicine,2008: Bridg...ar Diagnostics,in Cancer Therapeutic Development c...ber 3-6, at the ICC Jerusalem International Conven...
... Pa., Nov. 3 Environmental,Tectonics Corporation,...n,Division today announced the signing of a contra..., to add new capabilities to their ADMS-ARFF,Advan...cue Fire Fighting., The contract consists of the ...consisting of AH-64 Apache helicopters parked in a...
...a from randomized, double-blind, placebo controlle...ignificant reduction in recurrences ...AICA PLAIN, Mass., Nov. 3 /PRNewswire-FirstCall/,-...etts Biologic Laboratories,(MBL) of the University...unced that a Phase 2 trial of an anti-C. difficile...
Other Biology Technology:Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference 2Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference 3Environmental Tectonics Corporation's Simulation Division Receives New ADMS Contract from Netherlands Institute for Safety 2Environmental Tectonics Corporation's Simulation Division Receives New ADMS Contract from Netherlands Institute for Safety 3Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 2Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 3Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 4Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 5Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 6
(Date:12/3/2009)...QUE, N.M. Most scientists believe that staph infe...nal each other to emit toxins. The signaling proce...must be present to start the process. , But the ...e very first stage of staph infection, when bacter...rs in a single cell and that this individual proce...
(Date:12/3/2009)...researchers have measured CO2 levels for the past ...over a sparsely inhabited rural area near Valladol... in the Iberian Peninsula, show that the levels ro... recent years, physicists and meteorologists have ... levels, and how these have evolved in the troposp...
(Date:12/2/2009)...ELPHIA Less acculturated Latino men have a more d...more acculturated to U.S. culture, but acculturati...ng. Details of these findings are published in Ca...rnal of the American Association for Cancer Resear...cco. , "Acculturation affects smoking cessation ...
Breaking Biology News(10 mins):Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3CO2 levels rising in troposphere over rural areas 2Acculturation affects smoking cessation success among Latinos 2The Brain Comes Alive With the Sounds of Music 59818 1The Brain Comes Alive With the Sounds of Music 59818 2Full Results of AIDS Vaccine Trial Confirm Modest Benefit 59816 1Full Results of AIDS Vaccine Trial Confirm Modest Benefit 59816 2Full Results of AIDS Vaccine Trial Confirm Modest Benefit 59816 3Full Results of AIDS Vaccine Trial Confirm Modest Benefit 59816 4Henk Stunnenbergs lab applies Genomatix NextGen sequencing data analysis 59814 1
...DISON, WI, JUNE 2, 2008-- An understanding how env...teract to determine the transport and fate of agri... for effectively addressing the widespread degrada...nt, and future agricultural activities. While cons...maller scales, the holistic understanding of proce...
... team of Penn State scientists has discovered a ne...d for more than 120,000 years within the ice of a ... The microorganism,s ability to persist in this lo...nutrient-poor habitat makes it particularly useful... a variety of extreme environments on Earth and po...
...hens, Ga. The conventional wisdom among scientist...bacteria that are necessary for good health from t...study finds that chickens are actually born with t... the finding, presented this week at the American ..., could have important implications for the poultr...
Other Biology News:Holistic understanding: Ag chemicals in the environment 2A survivor in Greenland: A novel bacterial species is found trapped in 120,000-year-old ice 2Study finds healthy intestinal bacteria within chicken eggs 2
Rabbit Anti-Human Cytochrome P450 1A1 / 1A2 Polyclonal Antibody, Unconjugated from AbD Serotec
...-free cloning of BAC (100+kb), fosmid (40kb), and ...t stability than any othe BAC vector. On command 2...asy recombinant DNA purification. Available with b...e (pSMART VC) vectors for the highest insert stabi...
...-free cloning of BAC (100+kb), fosmid (40kb), and ...t stability than any othe BAC vector. On command 2...asy recombinant DNA purification. Available with b...e (pSMART VC) vectors for the highest insert stabi...
Rabbit Anti-GLYCINE Polyclonal Antibody, Unconjugated from AbD Serotec
Biology Products: